

ASX RELEASE

14 July 2023

**KAZIA THERAPEUTICS LIMITED (ASX: KZA; NASDAQ: KZIA) – CLEANSING NOTICE**

This notice is given by Kazia Therapeutics Limited (**Kazia**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

Reference is made to the Appendix 2A released to ASX on 14 July 2023 relating to the following issues of fully paid ordinary shares (**New Shares**):

- 8,148,140 New Shares issued on 7 July 2023 to existing shareholders at an issue price of USD 0.12283 per New Share; and
- 157,120 New Shares issued on 10 July 2023 to existing shareholders at an issue price of USD 0.11 per New Share.

In accordance with section 708A(6) of the Corporations Act, Kazia advises that:

- (a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, Kazia has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to Kazia; and
  - (ii) section 674 of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is "excluded information" within the meaning of sections 708A(7) or 708A(8) of the Corporations Act.

Yours sincerely



Anna Sandham  
Company Secretary

**Board of Directors**

**Mr Iain Ross** Chairman, Non-Executive Director  
**Mr Bryce Carmine** Non-Executive Director  
**Mr Steven Coffey** Non-Executive Director  
**Ms Ebru Davidson** Non-Executive Director